Immune Checkpoint Inhibitor Islet Function Impairment Risk: A Meta-Analysis of 31 RCTs

A systematic review and meta-analysis of 31 randomized controlled trials with 15,417 cancer patients, published by Qi Hu in 2026, assesses the risk of islet function impairment from immune checkpoint inhibitors. The data includes pooled risk ratios for outcomes like hyperglycemia, diabetes mellitus, and diabetic ketoacidosis, comparing ICPis to non-ICPis regimens. Subgroup analyses examine risks associated with specific drug types and cancer indications.

Use Cases

• Quantify the relative risk of hyperglycemia and diabetes based on pooled risk ratios from 31 RCTs.
• Compare the severity of adverse events (grade 3-5) between ICPis and non-ICPis treatment arms.
• Identify high-risk subgroups, such as patients on PD-1 inhibitors or with NSCLC, using subgroup analysis results.
• Assess the differential risk between ICPis monotherapy and combination therapy with chemotherapy.

Strengths

• Analysis is based on 31 randomized controlled trials, a robust study design for causal inference.
• Includes data from 15,417 patients, providing a substantial sample size for meta-analysis.
• Reports specific risk ratios with 95% confidence intervals and p-values for multiple outcomes and subgroups.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for direct ML modeling.
• The 268.1 KB file size suggests the dataset is a summary table, not the underlying patient-level data.

Provenance

Source

Qi Hu via figshare

Collection Method

Systematic review and meta-analysis of RCTs from PubMed, Embase, Cochrane, and Chinese databases.

Time Range

Literature search from database inception to October 24, 2024.

Freshness

Last updated 2026-03-19 06:49:58